[115]
Next, Novopharm alleges that the specification of the '080 patent is insufficient, as it fails to correctly and fully describe the invention as required by paragraph 34(1)(a) of the
Patent Act
, by citing inconsistent toxicity data. In the NOA, Novopharm alleged that if such omission was willfully made for the purposes of misleading the public, then the patent is void pursuant to subsection 53(1) of the
Patent Act
.